Citations 2
Prostate Cancer, Version 3.2024
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Bitting, Rhonda L. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gupta, Shilpa , Guzzo, Thomas, Karnes, R. Jeffrey , Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Snedeker, Jenna, Freedman-Cass, Deborah A., Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Gao, Xin Yuan , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Spratt, Daniel E. , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D.
Journal of the National Comprehensive Cancer Network | April 16, 2024 | Volume: 22 | Issue: 3 | Pages: 140-150
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Barocas, Daniel A. , Bitting, Rhonda L. , Bryce, Alan H. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Guzzo, Thomas, Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Shead, Dorothy A. , Snedeker, Jenna, Freedman-Cass, Deborah A., Bryce, Alan, Bryce, Alan H , Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Netto, George J. , Spratt, Daniel E. , Teply, Benjamin A. , Tward, Jonathan D.
Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1067-1096
The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.